Medical Device Hemocompatibility Evaluation: Blood Compatibility Testing According to ISO 10993-4

Hemocompatibility evaluation is a critical requirement for any medical device that contacts blood directly or indirectly, ensuring that the device does not trigger thrombosis, hemolysis, coagulation disorders, or inflammatory complement activation. This article provides a comprehensive technical overview of blood compatibility assessment according to ISO 10993-4, covering device categorization, test categories, sample requirements, methodologies, and regulatory applications for manufacturers preparing biocompatibility documentation.

Technical Overview

Hemocompatibility, or blood compatibility, refers to the ability of a medical device or biomaterial to perform its intended function in contact with blood without producing clinically significant adverse responses in the patient. Undesirable blood–device interactions include thrombus formation, activation of the coagulation cascade, platelet adhesion and activation, hemolysis (destruction of red blood cells), leukocyte activation, and complement activation, any of which can lead to serious clinical consequences such as embolism, thromboembolism, inflammation, organ damage, or immune reactions.

The framework for hemocompatibility evaluation is defined in ISO 10993-4, Biological evaluation of medical devices — Part 4: Selection of tests for interactions with blood, which works in conjunction with ISO 10993-1 (evaluation and testing within a risk management process) and ISO 10993-12 (sample preparation and reference materials). The Chinese national standard GB/T 16886.4 is the domestic adoption of this international standard and applies to registrations in the Chinese market.

ISO 10993-4 classifies blood-contacting devices according to the nature of blood contact, which directly determines the scope of testing required:

• Non-contact devices: devices that do not contact blood at all (for example, external operating room equipment), which generally require no blood compatibility assessment.
• External communicating devices — indirect blood path: devices through which fluids travel before eventually contacting the circulation, such as infusion sets, cannulae, and transfusion tubing.
• External communicating devices — circulating blood: devices contacting circulating blood directly, such as intravascular catheters, hemodialyzers, oxygenators, blood pumps, and apheresis consumables.
• Implant devices: devices placed within the vascular system for extended periods, such as stents, heart valves, vascular grafts, vena cava filters, and ventricular assist components.

Test selection also depends on contact duration (limited, prolonged, or permanent exposure), blood flow conditions (static versus dynamic, laminar versus turbulent), device geometry, materials of construction, and surface treatments. ISO 10993-4 organizes the required testing into five categories of blood interactions: thrombosis, coagulation, platelets, hematology, and the complement system. A scientifically justified test matrix, rather than an arbitrary checklist approach, is expected by regulators.

Testing Samples

Evaluation must be performed on the finished device in its final form, final manufacturing configuration, and final sterilization condition whenever possible, since processing residues, sterilization by-products, and surface finishes all influence blood compatibility. Typical sample categories submitted to accredited third-party laboratories or in-house biocompatibility facilities include the following:

Intravascular Catheters and Vascular Access Devices

Central venous catheters, peripherally inserted central catheters (PICC), peripheral intravenous catheters, introducer sheaths, guidewires, dialysis catheters, balloon catheters, and angiographic catheters. These devices contact circulating blood directly and therefore face the most demanding hemocompatibility requirements, typically requiring evaluation across thrombosis, coagulation, platelet, and hemolysis endpoints.

Extracorporeal Circulation Devices

Hemodialyzers, hemofilters, oxygenators (ECMO and cardiopulmonary bypass components), blood reservoirs, arterial line filters, blood tubing sets, and apheresis column consumables. Because these devices expose large blood-contacting surface areas to high shear stress over extended treatment durations, both hemolysis and complement activation are of particular concern.

Blood Collection, Storage, and Administration Devices

Blood collection tubes, blood bags, transfusion and infusion sets, syringes, needles, and infusion filters. Devices on the indirect blood path primarily require assessment of hemolysis and effects on coagulation, while blood storage containers additionally require evaluation of material effects on blood components over the storage period.

Cardiovascular and Vascular Implants

Coronary and peripheral stents, heart valve prostheses, vascular grafts, vena cava filters, stent grafts, and septal occluders. Permanent implants in the vascular system demand long-term thrombogenicity assessment, frequently requiring in vivo or ex vivo models in addition to in vitro screening.

Sample Preparation Requirements

Samples should represent production materials, processing, cleaning, and sterilization as delivered clinically. Extracts are prepared according to ISO 10993-12 using appropriate extraction vehicles and standardized surface-area-to-volume ratios, while direct contact testing uses the whole device or representative sections. Test reports should document lot numbers, sterilization method and residuals (for example, ethylene oxide), and any deviations from the as-supplied condition.

Testing Items

ISO 10993-4 structures the evaluation of blood–device interactions into five defined test categories, supplemented by the universally applied hemolysis assay. Specific endpoints within each category include:

• Thrombosis: qualitative and quantitative assessment of thrombus formation on the device or within the test circuit, including percent occlusion, thrombus mass, flow reduction, and flow-time profiles in dynamic or in vivo models.
• Coagulation: non-activated partial thromboplastin time (NAPTT) for the intrinsic pathway, prothrombin time (PT) for the extrinsic pathway, thrombin time (TT), thrombin generation assays, and plasma fibrinogen concentration.
• Platelets: platelet count, platelet adhesion and morphology on device surfaces (often by scanning electron microscopy), platelet aggregation, and activation markers such as P-selectin (CD62P), platelet factor 4 (PF4), and beta-thromboglobulin.
• Hematology: white blood cell count and differential count to detect leukocyte activation or depletion, red blood cell count, and peripheral blood cell morphology.
• Complement system: activation fragments C3a, C5a, and SC5b-9 (terminal complement complex), with particular relevance for extracorporeal circuits and dialyzer membranes.
• Hemolysis: plasma free hemoglobin concentration, calculation of the hemolysis ratio, and microscopic assessment of erythrocyte morphology.

The justified combination of these endpoints forms the device-specific test matrix. For example, a short-term indirect blood path device may only require hemolysis, NAPTT, and a platelet endpoint, whereas a chronic intravascular implant may require all five categories, including in vivo thrombogenicity testing.

Testing Methods

Method selection depends on device category, contact duration, and whether the device is intended to contact static or flowing blood. Both in vitro laboratory methods and animal-based in vivo or ex vivo models are recognized by ISO 10993-4.

Hemolysis Testing

Hemolysis testing is commonly performed in accordance with ASTM F756, Standard Practice for Assessment of Hemolytic Properties of Materials, using either the extract method or the direct contact method. In the extract method, an extract of the test article is incubated with diluted, freshly drawn anticoagulated blood; in the direct contact method, the material itself is incubated with blood. Following incubation at physiological temperature (37 °C), plasma free hemoglobin is measured spectrophotometrically. The hemolysis ratio is calculated by normalizing the sample value against negative controls (for example, saline extract or a known non-hemolytic reference) and positive controls (such as distilled water or a detergent solution). A hemolysis ratio of 5 percent or less is the widely applied acceptance benchmark indicating acceptable in vitro hemolytic behavior, consistent with GB/T 16886.4 guidance commonly referenced in regulatory submissions.

In Vitro Dynamic Blood Loop Testing

For devices exposed to flowing blood, dynamic models better simulate clinical conditions. Established approaches include the Chandler loop, closed recirculating flow loops driven by peristaltic or roller pumps, and annular or parallel-plate flow chambers. Fresh human or animal donor blood is circulated over or through the test device under controlled shear rates for defined periods, after which thrombus formation, cell counts, coagulation times, and activation markers are compared against reference materials and controls. Anticoagulant selection (unanticoagulated, heparinized, or citrated blood) is tailored to the endpoint being measured.

Ex Vivo and In Vivo Thrombogenicity Testing

Ex vivo evaluation uses an arteriovenous shunt model in an animal (commonly a dog, pig, or sheep), in which the test device is placed in the shunt circuit and blood flow is monitored in real time; flow reduction over time provides a quantitative index of thrombogenicity. In vivo testing involves implanting the device in a vessel (typically a vein or artery) of an anesthetized animal for a defined period, followed by gross and microscopic scoring of adherent thrombus. These animal studies must comply with ISO 10993-2 governing animal welfare requirements and should be justified within the risk assessment.

Coagulation, Platelet, and Complement Assays

Plasma-based coagulation assays (NAPTT, PT, TT) are performed on citrated plasma after controlled contact with device extracts or device surfaces, comparing results with negative controls and boundary limits. Platelet studies quantify adhesion, aggregation, and activation biomarkers, while complement activation is quantified by immunoassay of C3a, C5a, or SC5b-9 in human serum or plasma after contact with the device, which is especially important for hemodialysis and cardiopulmonary bypass components.

Test Design Considerations

Robust study design requires appropriate negative and positive controls, multiple donor blood lots to account for biological variability, defined incubation times and temperatures, validated analytical methods, and statistical comparison against acceptance criteria. Where extraction is used, extraction conditions must be justified according to ISO 10993-12 so that the test reflects worst-case clinical exposure rather than unrealistic exaggerated conditions.

Applications

Hemocompatibility evaluation data serve multiple purposes throughout the medical device lifecycle and are a mandatory component of biological evaluation documentation for blood-contacting devices in most major jurisdictions, including submissions to regulatory authorities in the United States, the European Union under the Medical Device Regulation, China, Japan, and other markets that recognize the ISO 10993 series. Typical applications include:

• Regulatory submissions: inclusion of ISO 10993-4 test results in 510(k), PMA, CE technical documentation, and national registration dossiers prepared with support from accredited third-party laboratories.
• Material and design screening: early comparative evaluation of candidate polymers, metals, coatings, and surface treatments (such as heparinized or hydrophilic coatings) before committing to full device testing.
• Design verification: confirmation that the final finished device meets predefined hemocompatibility acceptance criteria.
• Change control: re-evaluation following material changes, supplier changes, manufacturing process modifications, or sterilization changes that could affect blood-contacting surfaces.
• Clinical risk management: generation of objective evidence supporting the biological safety section of the ISO 14971 risk management file.

Specific device families that routinely require hemocompatibility data include cardiovascular devices, renal replacement and dialysis products, transfusion and infusion consumables, cardiac surgery and critical care extracorporeal circuits, interventional radiology devices, and temporary or permanent vascular implants.

FAQ

Which standard governs hemocompatibility evaluation of medical devices?

ISO 10993-4 defines the selection of tests for interactions with blood and is the primary international standard. It is used together with ISO 10993-1 for overall evaluation strategy and ISO 10993-12 for sample preparation. In China, the corresponding national standard GB/T 16886.4 applies, and ASTM F756 is widely used as the methodological reference for hemolysis testing.

Which devices require hemocompatibility testing?

Any device that contacts circulating blood directly, contacts an indirect blood path, or is implanted within the vasculature requires hemocompatibility evaluation. Devices with no blood contact do not require this testing. The specific test matrix is determined by the blood contact category defined in ISO 10993-4, the contact duration, and the intended use conditions.

What is the acceptance criterion for hemolysis?

A hemolysis ratio of 5 percent or less is the generally accepted benchmark for a material or device to be considered non-hemolytic or acceptably hemolytic in in vitro testing. Ratios above 5 percent generally warrant investigation of the cause, such as material selection, processing residues, sterilization effects, or excessive shear-inducing geometry.

Must all five test categories be performed for every blood-contacting device?

No. ISO 10993-4 requires a risk-based, scientifically justified selection. A short-term indirect blood path device may only need hemolysis and coagulation endpoints, whereas a chronic circulating blood implant may require thrombosis, coagulation, platelet, hematology, and complement testing, potentially including in vivo thrombogenicity studies. The rationale for test selection must be documented in the biological evaluation plan.

Why is testing performed on sterilized final products rather than raw materials alone?

Manufacturing, cleaning, and sterilization can alter surface chemistry, introduce extractable residues such as ethylene oxide or sterilant by-products, and change roughness or coating integrity. Because these factors materially influence blood compatibility, evaluation of the finished device in its as-delivered condition provides the most clinically relevant evidence of safety.

Can hemocompatibility testing replace other biocompatibility tests?

No. Hemocompatibility is one component of the complete biological evaluation required by ISO 10993-1, which typically also includes cytotoxicity (ISO 10993-5), sensitization and irritation (ISO 10993-10 and ISO 10993-23), systemic toxicity, genotoxicity, and implantation testing as applicable. Each endpoint addresses distinct biological hazards, and results must be integrated into the overall biological safety assessment and risk management file.